Poly Medicure Limited

Regd. Office: 232 B, 3rd Floor, Okhla Industrial Estate,

Phase-III, New Delhi - 110 020 (INDIA) T: +91-11- 33550700, 47317000

E: info@polymedicure.com W: polymedicure.com

CIN: L 40300DL1995PLC066923

Date: 13.11.2024

Scrip Code: - 531768

The Manager, BSE Limited, Department of Corporate Services, Phirozee Jeejeebhoy Towers, Dalal Street, Mumbai- 400001. Scrip Code:- POLYMED

The Manager National Stock Exchange of India Limited Exchange Plaza, Plot No. C/1-Block-G Bandra Kurla Complex, Bandra(E), Mumbai-400051.

POLYMED

Reg : - Regulation 32 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations").

Subject: - Statement of deviation(s) or variation(s), if any, of utilization of proceeds received from Qualified Institutions Placement (QIP).

Dear Sir/Madam,

We would like to inform that the Company had raised funds by way of allotment of 53,19,148 (Fifty Three Lakh Nineteen Thousand One Hundred Forty Eight) equity shares of face value of Rs. 5/- each, to qualified institutional buyers ("QIBs"), at a price of Rs. 1880/- per Equity Share (including premium of Rs. 1875/- per Equity Share), pursuant to the resolution passed by the Board of Directors dated 29th June, 2024, special resolution passed by the Shareholders through postal ballot on 5th August, 2024, the preliminary placement document dated 19th August, 2024, the placement document dated 22nd August, 2024 and resolution of the QIP Committee of the Board of Directors dated 22nd August, 2024 (the "Issue").

We would further like to inform that the Audit Committee, at its meeting held on October 28, 2024, has reviewed the actual utilization of funds received for an amount aggregating ~Rs 99,999.98 lakh, pursuant to the Issue.

In this connection, we submit that there is no deviation or variation from the objects of the Issue, in the utilization of proceeds, as stated in the placement document, during the quarter ended September 30, 2024.

In terms of Regulations 32(1), 32(2) and 32(3) of the SEBI Listing Regulations, a statement of deviation or variation, if any, in utilization of funds raised through Qualified Institutions Placement (QIP), for the quarter ended September 30, 2024, duly reviewed by the Audit Committee, in the prescribed format is also enclosed herewith

This is for your information and record.

For Poly Medicure Limited

Avinash Chandra Company Secretary M. No. A32270 Name Death I

Statement of Deviation / Variation in utilization of fu				
Name of listed entity	Poly Medicure Limited			
Mode of Fund Raising	Qualified Institutions Placement (QIP)			
Date of Raising Funds	Issue Open Date :19.08.2024			
	Issue Closing Date :22.08.2024			
	Date of allotment of equity shares: 22.08.2024			
Amount Raised	Rs 99,999.98 lakh (approx.)			
Report filed for Quarter ended	September 30, 2024			
Monitoring Agency	Applicable			
Monitoring Agency Name, if applicable	CRISIL Ratings Limited			
Is there a Deviation / Variation in use of funds raised	NO			
If yes, whether the same is pursuant to change in terms	Not Applicable			
of a contract or objects, which was approved by the				
shareholders				
If Yes, Date of shareholder Approval	Not Applicable			
Explanation for the Deviation / Variation	Not Applicable			
Comments of the Audit Committee after review	No comments			
Comments of the auditors, if any	No comments			

Objects for which funds have been raised and where there has been a deviation, in the following table

Original Object	Modified	Original	Modified	Funds	Amount of	Remark s if
	Object, if	Allocation	allocation, if	Utilized	Deviation/	any
	any	(Amount	any (Amount	(Amount	Variation for	
	**	in Lakhs)	in Lakhs)	in Lakhs)	the quarter according to applicable Object	
(a) Funding capital expenditure to be incurred by Company for setting up of manufacturing facilities.	N.A.	49,973.16	N.A.	•	N.A.	*
(b)Pursuing inorganic initiatives	N.A.	25,026.84	N.A.	-	N.A.	
(c) General corporate purposes	N.A.	23,499.98	N.A.	8,499.00	N.A.	
Total		98,499.98 *(net of issue expenses)		8,499.00		¥

*The actual issue proceeds come to ~Rs.99,999.98 lakh and as per placement document, the expenses related to the issue were estimated at Rs. 1500 Lakhs.

Deviation or variation could mean:

- (a) Deviation in the objects or purposes for which the funds have been raised or
- (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or

(c) Change in terms of account referred to in the fund-raising document i.e., prospectus, letter of offer, etc.

Naresh Vijayvergiya Chief Financial Officer

Date: 13.11.2024